Wells Fargo & Company MN Sells 21,533 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Wells Fargo & Company MN trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 152,508 shares of the biopharmaceutical company’s stock after selling 21,533 shares during the period. Wells Fargo & Company MN owned about 0.14% of Regeneron Pharmaceuticals worth $108,636,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. OFI Invest Asset Management bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Rakuten Securities Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares during the last quarter. Avalon Trust Co acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $36,000. Crowley Wealth Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $36,000. Finally, Private Wealth Management Group LLC lifted its position in Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 39 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $572.78 on Tuesday. The stock has a 50-day moving average price of $674.46 and a two-hundred day moving average price of $772.53. Regeneron Pharmaceuticals, Inc. has a 1 year low of $557.83 and a 1 year high of $1,211.20. The stock has a market cap of $62.62 billion, a PE ratio of 14.96, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the firm earned $11.86 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.61%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Analyst Ratings Changes

Several research firms have weighed in on REGN. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Finally, TD Cowen cut their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $966.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.